Pfizer, Moderna, Bristol Myers trade on terminal value

Pfizer has climbed to $25.41, up from $23.26 in late June, with the shares back above both the 50-day and 200-day moving averages and momentum indicators improving. Bristol Myers has gone further, rising to $65.89 from $54.38 in late January, a move that reflects just how aggressively the market is rewarding companies that can prove earnings durability and product mix strength. Moderna, by contrast, is still trying to hold the line after a violent summer run and pullback, with the stock at $56.99 after a surge to $81.80 in early July, a sign that investors are still struggling to pin down a steady terminal value for a company whose earnings can swing wildly with vaccine demand and litigation costs.

The deeper story is that healthcare sentiment is now a contrarian setup. Adalytica’s Healthcare Spending Sentiment gauge shows “Extreme Fear” at 4, even as awareness sits at “Extreme Greed” at 100. That kind of disconnect usually shows up when the market is loudly debating near-term risks but underappreciating what happens if revenue stabilizes, capital returns improve or operating leverage starts to show through. For long-term investors, that is exactly when the best opportunities tend to appear.

Pfizer is the clearest example. The company has already reaffirmed 2026 revenue of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, which gives investors a concrete base to model rather than a story built on hope. At roughly 24.9 times book-adjusted trading momentum is not the real point; the real question is whether Pfizer can defend margin assumptions as it works through post-pandemic normalization and pipeline execution. If the market starts to believe that the earnings floor is higher than feared, even a modest re-rating in terminal multiple can drive outsized upside from here.

Moderna is the opposite case, and that is what makes it investable in a different way. The company’s latest quarter showed a sharp swing in product sales tied to international COVID vaccine deliveries and manufacturing revenue, but its cost structure and litigation burden are still making valuation models hard to trust. The stock’s huge range this year tells you the market is not anchoring on a clean normalized earnings stream. For investors, that means Moderna remains a high-beta optionality trade, not a classic DCF compounder.

Bristol Myers, meanwhile, is the proof that pharma can still command a premium when cash generation and pipeline visibility align. The stock’s steady climb toward $66 reflects investor confidence that its growth portfolio can offset erosion elsewhere, and that is precisely the sort of business where a lower discount rate and a firmer terminal multiple can produce material valuation expansion. In other words, the market is rewarding certainty over narrative.

The investable takeaway is simple: do not treat big-cap pharma as a monolith. The opportunity is in separating stable cash generators from binary science bets, then owning the names where the market is still applying too much fear to terminal value. If you want the asymmetric setup, favor the companies with visible earnings power, improving technicals and the ability to defend margins through the next cycle. That is where DCFs stop being abstract math and start becoming a source of alpha.